Amount of qualified clients: CDEC discussed the uncertainty in the number of individuals with moderately intense to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some clients that are labeled as possessing gentle or moderate disease can have a extreme bleeding phenotype